Ironwood Pharmaceuticals | IRWD - Operating Expenses


Ironwood Pharmaceuticals reported $57.33M in Operating Expenses for its fiscal quarter ending in December of 2024.





Operating Expenses Change Date
Acadia Pharmaceuticals USD 242.88M 10.68M Sep/2025
Agios Pharmaceuticals USD 141.54M 11.8M Dec/2025
Akebia Therapeutics USD 43.82M 16.98M Mar/2025
Almirall EUR 517.4M 32K Dec/2025
Alnylam Pharmaceuticals USD 965.32M 84.27M Dec/2025
Amarin USD 51.37M 14.6M Sep/2025
Ardelyx USD 105.66M 6.4M Sep/2025
Astellas Pharma JPY 436.66B 16.75B Dec/2025
AstraZeneca USD 12.53B 4.16B Dec/2025
Charles River Laboratories USD 918.41M 2.49B Dec/2025
Coherus Biosciences USD 53.03M 43.41M Mar/2025
Emergent BioSolutions USD 555.9M 242.7M Jun/2023
Esperion Therapeutics USD 67.66M 3.6M Sep/2024
Exact Sciences USD 875.74M 62.51M Sep/2025
Halozyme Therapeutics USD 211.07M 74.73M Dec/2025
Incyte USD 1.12B 3.53B Dec/2025
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Karyopharm Therapeutics USD 61.82M 3.24M Dec/2024
Lexicon Pharmaceuticals USD 57M 10.54M Jun/2024
MacroGenics USD 67M 8M Sep/2025
Moderna USD 1.54B 259M Dec/2025
Myriad Genetics USD 229M 3.4M Sep/2025
Pacira USD 166.36M 4.5M Sep/2025
PTC Therapeutics USD 246.3M 38.78M Dec/2025
Puma Biotechnology USD 49.26M 3.2M Jun/2024
Sarepta Therapeutics USD 462.23M 33.28M Sep/2025
Takeda JPY 1.02T 400.98B Dec/2025
Ultragenyx Pharmaceutical USD 321M 9.82M Dec/2025
Vanda Pharmaceuticals USD 466M 20.33M Sep/2025